Novel oral anticoagulants may be the best defense against intracranial hemorrhage (ICH) when used to prevent strokes in patients with atrial fibrillation, based on the findings of a meta-analysis published in the December issue of JAMA Neurology.

Are clinical trial names prophetic? PREVAIL may provide the answer.

An advisory panel to the FDA voted in favor of approval of the Watchman Left Atrial Appendage Closure device as an alternative to warfarin for people with atrial fibrillation who are at risk of strokes.

Patients with obstructive sleep apnea and resistant hypertension who used continuous positive airway pressure had lower blood pressure over a 12-week period, according to a study published online Dec. 11 in JAMA.  

Erectile dysfunction (ED) has been proposed as a harbinger of coronary artery disease. In the November issue of the Journal of Men’s Health, two physicians suggest that ED and hypertension may be linked as well.

Medtronic, Inc. (NYSE: MDT), announced today CE Mark (Conformité Européenne) in Europe and Therapeutic Goods Administration (TGA) listing in Australia for its highly flexible 4 Fr multi-electrode Symplicity Spyral™ catheter and Symplicity G3™ radio frequency (RF) generator. 

The number of stroke deaths decreased considerably throughout the 20th century, and the American Heart Association/American Stroke Association wrote in a scientific statement published in the January 2014 issue of Stroke that the trend is the result of the aggressive management of risk factors.

Chosen for nearly one out of every two endovascular abdominal aortic aneurysm (AAA) repairs worldwide, the Endurant II AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to demonstrate long-term durability and consistent outcomes at three years in a real-world setting.